PTGS2 and juvenile Huntington disease: Essentially, abrogation of TNF-α and IL-6 alongside COX-2 downregulation mediated the neuroprotective effects of meloxicam in experimental LPS-evoked brain neuroinflammation [48], quinolinic acid-induced Huntington’s disease-like manifestations [49], and in a painful nerve root injury model [32].